Acciones de intellia therapeutics inc
17 Jul 2018 Las acciones de las compañías de edición de genes CRISPR Therapeutics AG, Editas Medicine Inc, Sangamo Therapeutics Inc e Intellia 12/5/2019 · Información financiera sobre las acciones de Intellia Therapeutics Inc (NTLA), incluyendo precio de las acciones, último cierre, volumen, variación en 1 año, rango intradía, rango de 52 semanas, capitalización bursátil, ingresos, dividendo etc. de NTLA. 11/28/2019 · Consulta las últimas cotizaciones de acciones, historial, noticias y otra información vital de Intellia Therapeutics, Inc. (NTLA) para ayudarte con tus 8/24/2016 · Las noticias más recientes sobre Intellia Therapeutics Inc y la cotización de las acciones de NTLA en bolsa, última hora y mucho más en Investing.com. Intellia Therapeutics Inc Intellia Therapeutics Inc. (anteriormente conocida como AZRN Inc.) se fundó en 2014 y su sede se ubica en Cambridge, Massachusetts. La empresa se centra actualmente en la edición genética y el desarrollo de terapias basadas en una herramienta biológica única llamada sistema CRISPR/Cas9. 9/8/2010 · Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as Reciba gratis sus datos actualizados y en vivo para Intellia Therapeutics Inc - Cotización, gráficos, precios, análisis, noticias y pronósticos para NTLA.
6/19/2017 · Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China Patent covers CRISPR/Cas9 gene editing methods and compositions for use in any setting, including human and other eukaryotic cells
Intellia Therapeutics, Inc. Common Stock (NTLA) News Headlines. Oct 24, 2019. There's Yet Another Gene Editing Technique, but It Has 1 Glaring Problem. Oct 2, 2019. Get Intellia Therapeutics Inc (NTLA:NASDAQ) real-time stock quotes, news and financial information from CNBC. Free current stock price quotes and data for Intellia Therapeutics Inc (NTLA). Research news, charts, stock market performance and earnings. About Intellia Therapeutics Inc. Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. Intellia Therapeutics Inc.’s 183.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 2.83 beta. Liquidity. 10.2 and 10.2 are the respective Current Ratio and a Quick Ratio of Oragenics Inc. Its rival Intellia Therapeutics Inc.’s Current and Quick Ratios are 7.9 and 7.9 respectively. CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), will present today new data, including the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates (NHPs), at the 22 nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place Frequency. Recurring Once. Follow Intellia Therapeutics Inc's earnings. For all future releases Just for the upcoming release Send me a reminder 1 trading day before
Natha - Musik (MP3 free auf www.ingrow.de)
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. About Intellia Therapeutics Inc Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. 11/30/2019 · Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics Inc (NASDAQ:NTLA) by 8.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,691 shares of the company’s stock after purchasing an additional 4,528 shares during the quarter. 12/21/2019 · BlackRock Inc. boosted its stake in Intellia Therapeutics by 6.6% during the 2nd quarter. BlackRock Inc. now owns 3,390,267 shares of the company’s stock worth $55,499,000 after purchasing an additional 208,548 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 13.2% during the 2nd quarter. BBVA Banco Frances SA BED BATH & Beyond INC Concrete Pumping Holdings INC Banco Bradesco-ADR Banco Bradesco SA Bridgebio Pharma INC BHP Group PLC Sponsored ADR Barrett Business SVCS INC BB&T CORP Banco Bilbao Vizcaya-SP ADR BBX Capital CORP…
Cotizacion de INTELLIA THERAPEUTICS INC.: datos históricos y INC. 15,38 USD (-2,90%). 27/12/2019 - 12:59 15 minutos de retraso - Acciones NASDAQ
En eToro puedes comprar acciones de $NTLA o cualquier otro y paga CERO comisiones! Sigue la cotizacion de Intellia Therapeutics Inc y obtén más información. Consulta las últimas cotizaciones de acciones, historial, noticias y otra información vital de Intellia Therapeutics, Inc. (NTLA) para ayudarte con tus operaciones En Yahoo Finanzas, encontrarás gratis cotizaciones de acciones, noticias actualizadas, recursos de gestión de cartera de Intellia Therapeutics, Inc. (NTLA). Intellia Therapeutics, Inc. Common Stock (NTLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Today's High Today's Low 52 Week High 52 Week Low. Copyright West LLC. Minimum 15 minutes delayed. Contact IR
17 Jul 2018 Las acciones de las compañías de edición de genes CRISPR Therapeutics AG, Editas Medicine Inc, Sangamo Therapeutics Inc e Intellia 12/5/2019 · Información financiera sobre las acciones de Intellia Therapeutics Inc (NTLA), incluyendo precio de las acciones, último cierre, volumen, variación en 1 año, rango intradía, rango de 52 semanas, capitalización bursátil, ingresos, dividendo etc. de NTLA.
About Intellia Therapeutics Inc Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. 11/30/2019 · Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics Inc (NASDAQ:NTLA) by 8.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,691 shares of the company’s stock after purchasing an additional 4,528 shares during the quarter. 12/21/2019 · BlackRock Inc. boosted its stake in Intellia Therapeutics by 6.6% during the 2nd quarter. BlackRock Inc. now owns 3,390,267 shares of the company’s stock worth $55,499,000 after purchasing an additional 208,548 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 13.2% during the 2nd quarter.